Observational Study of Cannabis Use and Quality of Life in Adults with Newly Diagnosed Multiple Myeloma Undergoing First Line Chemotherapy

What this Trial Is About

Researchers are evaluating how cannabis use affects the quality of life in patients with multiple myeloma who are receiving chemotherapy. This observational study compares patients who use cannabis with those who do not, aiming to understand both potential benefits and harms. It uses specific tools like the Functional Assessment of Cancer Therapy-Multiple Myeloma FACT-MM and patient-reported symptoms to assess these effects over time. Participants are divided into two groups one group completes surveys and provides blood samples throughout the study, and the other group consists of healthcare providers who complete a survey related to the study. The study follows participants for up to one year, focusing on longitudinal patterns in quality of life and the potential therapeutic benefits and adverse effects associated with cannabis use. During the study, patients complete questionnaires and provide blood samples regularly. Researchers monitor their symptoms and any side effects using standardized scales such as the Edmonton Symptoms Assessment Scale and Common Terminology Criteria for Adverse Events. The study tracks changes over time to better understand how cannabis use interacts with cancer-directed treatments and overall patient well-being.

A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients